Cocoon Bioscience utilizes a proprietary platform that automates the production of complex recombinant proteins and enzymes using insects in a chrysalis state, significantly reducing costs and infrastructure needs. This technology addresses the limitations of traditional bioreactor systems by providing scalable and efficient solutions for protein production in healthcare and nutrition applications.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of producing complex recombinant proteins and enzymes often rely on bioreactor systems, which can be expensive, require significant infrastructure, and may struggle with the complexities of certain proteins. This creates bottlenecks in development and limits scalability for healthcare and nutrition applications.
Solution
Cocoon Bioscience offers a platform that automates the production of complex recombinant proteins and enzymes using insects in a chrysalis state, providing a cost-effective and scalable alternative to traditional bioreactors. By leveraging this natural system, the platform streamlines the production process, reduces infrastructure and material requirements, and optimizes production capabilities. This approach enables the production of complex proteins that are difficult to achieve with traditional systems, unblocking industry bottlenecks and accelerating development projects. The platform offers linear, rapid, and adaptable scalability from milligrams to kilograms, empowering partners to effectively handle varying volume supply needs.
Target Audience
The primary customers are companies in the healthcare and nutrition industries that require complex recombinant proteins and enzymes for research, development, and manufacturing.
Features
- Automated protein production using insects in a chrysalis state
- Production of growth factors and enzymes
- Scalable production from milligrams to kilograms
- Cost-effective compared to traditional bioreactor systems
- Production of complex proteins that are difficult to achieve with traditional systems